ArticleLife (Basel, Switzerland)2026
Construction and Characterization of an Attenuated Vaccine Vector Based on Cucumber Mosaic Virus RNA2.
Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Plant viruses are major plant pathogens and account for nearly half of emerging plant diseases worldwide. To date, few effective management measures are available for the efficient control of plant viral diseases. Cross-protection based on attenuated vaccine is an effective strategy to prevent plant viral diseases. The primary requirement for the development of attenuated vaccines is a vector with excellent characteristics, such as low pathogenicity, genetic stability, and the capacity for stable insertion of exogenous fragments. In this study, the cucumber mosaic virus (Fny strain) was genetically modified to serve as an attenuated vaccine vector. Based on pre-termination of the 2b protein-coding region and deletion of the 3' UTR in CMV RNA2, six RNA2 mutants, designated R2-2bPTI, R2-2bPTII, R2-2bPTIII, R2-2bPTIV, R2-2bPTV, and R2-2bPTVI, were constructed. Experiments with different lengths tobacco phytoene desaturase (PDS) fragment insertion evaluated the capacity of each mutant to accommodate exogenous fragment. Based on the R2-2bPTIV, a viral fragment insertion mutant R2-2bPTIV-TMPYTVPX targeting cucumber mosaic virus (CMV), tobacco mosaic virus (TMV), potato virus Y (PVY), tobacco vein banding mosaic virus (TVBMV), and potato virus X (PVX) was constructed. This mutant provided effective cross-protection against these targeted virulent viruses. This study developed a series of CMV-based vaccine vector, providing materials and data for the development of plant viral diseases attenuated vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.